Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

1,2,4-Triazolsulfone: A novel isosteric replacement of acylsulfonamides in the context of NaV1.7 inhibition.

Boezio AA, Andrews K, Boezio C, Chu-Moyer M, Copeland KW, DiMauro EF, Foti RS, Fremeau RT Jr, Gao H, Geuns-Meyer S, Graceffa RF, Gunaydin H, Huang H, La DS, Ligutti J, Moyer BD, Peterson EA, Yu V, Weiss MM.

Bioorg Med Chem Lett. 2018 Jun 15;28(11):2103-2108. doi: 10.1016/j.bmcl.2018.04.035. Epub 2018 Apr 17.

PMID:
29709252
2.

Polymorphic Human Sulfotransferase 2A1 Mediates the Formation of 25-Hydroxyvitamin D3-3-O-Sulfate, a Major Circulating Vitamin D Metabolite in Humans.

Wong T, Wang Z, Chapron BD, Suzuki M, Claw KG, Gao C, Foti RS, Prasad B, Chapron A, Calamia J, Chaudhry A, Schuetz EG, Horst RL, Mao Q, de Boer IH, Thornton TA, Thummel KE.

Drug Metab Dispos. 2018 Apr;46(4):367-379. doi: 10.1124/dmd.117.078428. Epub 2018 Jan 17.

PMID:
29343609
3.

The UltraSound-CLinical ARthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis.

Salaffi F, Di Carlo M, Iannone F, Fedele AL, Epis OM, Pellerito R, Foti R, Passiu G, Punzi L, Furini F, Sarzi-Puttini P, Carletto A, Gremese E, Lapadula G, Ferraccioli G.

Semin Arthritis Rheum. 2018 Apr;47(5):619-629. doi: 10.1016/j.semarthrit.2017.09.013. Epub 2017 Sep 28.

PMID:
29102157
4.

Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.

Iannone F, Ferraccioli G, Sinigaglia L, Favalli EG, Sarzi-Puttini P, Atzeni F, Gorla R, Bazzani C, Govoni M, Farina I, Gremese E, Carletto A, Giollo A, Galeazzi M, Foti R, Bianchino L, La Grasta L, Lapadula G.

Clin Rheumatol. 2018 Feb;37(2):315-321. doi: 10.1007/s10067-017-3846-8. Epub 2017 Oct 5.

PMID:
28980085
5.

Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs.

Atzeni F, Carletto A, Foti R, Sebastiani M, Panetta V, Salaffi F, Bonitta G, Iannone F, Gremese E, Govoni M, Marchesoni A, Favalli EG, Gorla R, Ramonda R, Sarzi-Puttini P, Ferraccioli G, Lapadula G; GISEA group.

Joint Bone Spine. 2018 Jul;85(4):455-459. doi: 10.1016/j.jbspin.2017.08.003. Epub 2017 Sep 8.

PMID:
28893679
6.

Discovery of a biarylamide series of potent, state-dependent NaV1.7 inhibitors.

Schenkel LB, DiMauro EF, Nguyen HN, Chakka N, Du B, Foti RS, Guzman-Perez A, Jarosh M, La DS, Ligutti J, Milgram BC, Moyer BD, Peterson EA, Roberts J, Yu VL, Weiss MM.

Bioorg Med Chem Lett. 2017 Aug 15;27(16):3817-3824. doi: 10.1016/j.bmcl.2017.06.054. Epub 2017 Jun 26.

PMID:
28684121
7.

Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Benucci M, Gobbi FL, Guiducci S, Foti R, Mosca M, Goletti D.

Semin Arthritis Rheum. 2017 Oct;47(2):183-192. doi: 10.1016/j.semarthrit.2017.03.008. Epub 2017 Mar 22. Review.

PMID:
28413099
8.

Correction to "Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement".

Marx IE, Dineen TA, Able J, Bode C, Bregman H, Chu-Moyer M, DiMauro EF, Du B, Foti RS, Fremeau RT Jr, Gao H, Gunaydin H, Hall BE, Huang L, Kornecook T, Kreiman CR, La DS, Ligutti J, Lin MJ, Liu D, McDermott JS, Moyer BD, Nguyen HN, Peterson EA, Roberts JT, Rose P, Wang J, Youngblood BD, Yu V, Weiss MM.

ACS Med Chem Lett. 2017 Feb 28;8(3):378. doi: 10.1021/acsmedchemlett.7b00075. eCollection 2017 Mar 9.

9.

Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.

Graceffa RF, Boezio AA, Able J, Altmann S, Berry LM, Boezio C, Butler JR, Chu-Moyer M, Cooke M, DiMauro EF, Dineen TA, Feric Bojic E, Foti RS, Fremeau RT Jr, Guzman-Perez A, Gao H, Gunaydin H, Huang H, Huang L, Ilch C, Jarosh M, Kornecook T, Kreiman CR, La DS, Ligutti J, Milgram BC, Lin MJ, Marx IE, Nguyen HN, Peterson EA, Rescourio G, Roberts J, Schenkel L, Shimanovich R, Sparling BA, Stellwagen J, Taborn K, Vaida KR, Wang J, Yeoman J, Yu V, Zhu D, Moyer BD, Weiss MM.

J Med Chem. 2017 Jul 27;60(14):5990-6017. doi: 10.1021/acs.jmedchem.6b01850. Epub 2017 Apr 20.

PMID:
28324649
10.

Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities.

Weiss MM, Dineen TA, Marx IE, Altmann S, Boezio A, Bregman H, Chu-Moyer M, DiMauro EF, Feric Bojic E, Foti RS, Gao H, Graceffa R, Gunaydin H, Guzman-Perez A, Huang H, Huang L, Jarosh M, Kornecook T, Kreiman CR, Ligutti J, La DS, Lin MJ, Liu D, Moyer BD, Nguyen HN, Peterson EA, Rose PE, Taborn K, Youngblood BD, Yu V, Fremeau RT Jr.

J Med Chem. 2017 Jul 27;60(14):5969-5989. doi: 10.1021/acs.jmedchem.6b01851. Epub 2017 Apr 20.

PMID:
28287723
11.

Using a modified Delphi process to establish clinical consensus for the diagnosis, risk assessment and abatacept treatment in patients with aggressive rheumatoid arthritis.

Caporali R, Carletto A, Conti F, D'Angelo S, Foti R, Gremese E, Govoni M, Iannone F, Pellerito R, Sinigaglia L.

Clin Exp Rheumatol. 2017 Sep-Oct;35(5):772-776. Epub 2017 Mar 3.

PMID:
28281459
12.

Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement.

Marx IE, Dineen TA, Able J, Bode C, Bregman H, Chu-Moyer M, DiMauro EF, Du B, Foti RS, Fremeau RT Jr, Gao H, Gunaydin H, Hall BE, Huang L, Kornecook T, Kreiman CR, La DS, Ligutti J, Lin MJ, Liu D, McDermott JS, Moyer BD, Peterson EA, Roberts JT, Rose P, Wang J, Youngblood BD, Yu V, Weiss MM.

ACS Med Chem Lett. 2016 Sep 21;7(12):1062-1067. eCollection 2016 Dec 8. Erratum in: ACS Med Chem Lett. 2017 Feb 28;8(3):378.

13.

Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen.

Foti R, Visalli E, Amato G, Benenati A, Converso G, Farina A, Bellofiore S, Mulè M, Di Gangi M.

Rheumatol Int. 2017 Feb;37(2):245-249. doi: 10.1007/s00296-016-3582-4. Epub 2016 Oct 28.

14.

Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors.

DiMauro EF, Altmann S, Berry LM, Bregman H, Chakka N, Chu-Moyer M, Bojic EF, Foti RS, Fremeau R, Gao H, Gunaydin H, Guzman-Perez A, Hall BE, Huang H, Jarosh M, Kornecook T, Lee J, Ligutti J, Liu D, Moyer BD, Ortuno D, Rose PE, Schenkel LB, Taborn K, Wang J, Wang Y, Yu V, Weiss MM.

J Med Chem. 2016 Sep 8;59(17):7818-39. doi: 10.1021/acs.jmedchem.6b00425. Epub 2016 Aug 29.

PMID:
27441383
15.
16.

Discovery and in Vivo Evaluation of the Potent and Selective PI3Kδ Inhibitors 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-0687) and 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-5-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-1430).

Gonzalez-Lopez de Turiso F, Hao X, Shin Y, Bui M, Campuzano ID, Cardozo M, Dunn MC, Duquette J, Fisher B, Foti RS, Henne K, He X, Hu YL, Kelly RC, Johnson MG, Lucas BS, McCarter J, McGee LR, Medina JC, Metz D, San Miguel T, Mohn D, Tran T, Vissinga C, Wannberg S, Whittington DA, Whoriskey J, Yu G, Zalameda L, Zhang X, Cushing TD.

J Med Chem. 2016 Aug 11;59(15):7252-67. doi: 10.1021/acs.jmedchem.6b00827. Epub 2016 Jul 25.

PMID:
27411843
17.

Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics.

Foti RS, Dalvie DK.

Drug Metab Dispos. 2016 Aug;44(8):1229-45. doi: 10.1124/dmd.116.071753. Epub 2016 Jun 13. Erratum in: Drug Metab Dispos. 2016 Sep;44(9):1516.

18.

Identification of Tazarotenic Acid as the First Xenobiotic Substrate of Human Retinoic Acid Hydroxylase CYP26A1 and CYP26B1.

Foti RS, Isoherranen N, Zelter A, Dickmann LJ, Buttrick BR, Diaz P, Douguet D.

J Pharmacol Exp Ther. 2016 May;357(2):281-92. doi: 10.1124/jpet.116.232637. Epub 2016 Mar 2.

19.

Efficacy of cyclosporine A as monotherapy in patients with psoriatic arthritis: a subgroup analysis of the SYNERGY Study.

Colombo D, Chimenti S, Grossi PA, Marchesoni A, Foti R, Calzavara-Pinton P, Zagni E, Ori A, Bellia G; SYNERGY Study Group.

G Ital Dermatol Venereol. 2017 Jun;152(3):297-301. doi: 10.23736/S0392-0488.16.05301-3. Epub 2016 Feb 2.

PMID:
26837484
20.

Nuclear Architecture Organized by Rif1 Underpins the Replication-Timing Program.

Foti R, Gnan S, Cornacchia D, Dileep V, Bulut-Karslioglu A, Diehl S, Buness A, Klein FA, Huber W, Johnstone E, Loos R, Bertone P, Gilbert DM, Manke T, Jenuwein T, Buonomo SC.

Mol Cell. 2016 Jan 21;61(2):260-73. doi: 10.1016/j.molcel.2015.12.001. Epub 2015 Dec 24.

21.

Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.

Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Biggioggero M, Benucci M, Li Gobbi F, Grossi V, Infantino M, Meacci F, Manfredi M, Guiducci S, Bellando-Randone S, Matucci-Cerinic M, Foti R, Di Gangi M, Mosca M, Tani C, Palmieri F, Goletti D; Italian board for the TAilored BIOlogic therapy (ITABIO).

Semin Arthritis Rheum. 2016 Apr;45(5):519-32. doi: 10.1016/j.semarthrit.2015.10.001. Epub 2015 Oct 22. Review.

PMID:
26607440
22.

Potent and Selective Inhibition of Plasma Membrane Monoamine Transporter by HIV Protease Inhibitors.

Duan H, Hu T, Foti RS, Pan Y, Swaan PW, Wang J.

Drug Metab Dispos. 2015 Nov;43(11):1773-80. doi: 10.1124/dmd.115.064824. Epub 2015 Aug 18.

23.

An observational cohort study of patients with newly diagnosed digital ulcer disease secondary to systemic sclerosis registered in the EUSTAR database.

Brand M, Hollaender R, Rosenberg D, Scott M, Hunsche E, Tyndall A, Denaro V, Carreira P, Varju C, Gabrielli B, Zingarelli S, Caramaschi P, Simic-Pasalic K, Müller-Ladner U, Vasile M, Mihai C, Rosato E, Vacca A, Zenone T, Mohamed WA, Ancuta C, Zampogna G, Rednic S, Jabaar N, Belloli L, Pozzi MR, Foti R, Walker UA; EUSTAR Co-Investigators.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S47-54. Epub 2015 Aug 5.

PMID:
26243652
24.

Long-term survival in a patient with muscle-eye-brain disease.

Falsaperla R, Giunta L, Lubrano R, Foti R, Vitaliti G.

Neurol Sci. 2015 Nov;36(11):2147-9. doi: 10.1007/s10072-015-2321-z. Epub 2015 Jul 8. No abstract available.

PMID:
26152802
25.

Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial.

Gianfreda D, Nicastro M, Galetti M, Alberici F, Corradi D, Becchi G, Baldari G, De Filippo M, Ferretti S, Moroni G, Foti R, Di Gangi M, Jeannin G, Saffroy R, Emile JF, Buzio C, Vaglio A.

Blood. 2015 Sep 3;126(10):1163-71. doi: 10.1182/blood-2015-01-620377. Epub 2015 Jun 3.

26.

"Target-Site" Drug Metabolism and Transport.

Foti RS, Tyndale RF, Garcia KL, Sweet DH, Nagar S, Sharan S, Rock DA.

Drug Metab Dispos. 2015 Aug;43(8):1156-68. doi: 10.1124/dmd.115.064576. Epub 2015 May 18.

27.

Induction of CYP26A1 by metabolites of retinoic acid: evidence that CYP26A1 is an important enzyme in the elimination of active retinoids.

Topletz AR, Tripathy S, Foti RS, Shimshoni JA, Nelson WL, Isoherranen N.

Mol Pharmacol. 2015;87(3):430-41. doi: 10.1124/mol.114.096784. Epub 2014 Dec 9.

28.

Long-term efficacy of adalimumab in hyperimmunoglobulin D and periodic fever syndrome.

Di Gangi M, Amato G, Converso G, Benenati A, Leonetti C, Borella E, Doria A, Foti R.

Isr Med Assoc J. 2014 Oct;16(10):605-7. No abstract available.

29.

Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register.

Sebastiani M, Anelli MG, Atzeni F, Bazzani C, Farina I, Fedele AL, Favalli EG, Fineschi I, Cino N, Dal Forno I, Gasparini S, Cassarà E, Giardina R, Bruschi E, Addimanda O, Cassone G, Lopriore S, Sarzi-Puttini P, Filippini M, Pignatti F, Gremese E, Biggioggero M, Manganelli S, Amato G, Caimmi C, Salaffi F, Iannone F, Ferri C, Sandri G, Lapadula G, Gorla R, Govoni M, Ferraccioli G, Marchesoni A, Galeazzi M, Foti R, Carletto A, Cantini F, Triolo G, Epis OM, Salvarani C; Italian Study Group on Early Arthritides (GISEA).

Joint Bone Spine. 2014 Dec;81(6):508-12. doi: 10.1016/j.jbspin.2014.06.011. Epub 2014 Jul 28.

PMID:
25082646
30.

Characterization of the active site properties of CYP4F12.

Eksterowicz J, Rock DA, Rock BM, Wienkers LC, Foti RS.

Drug Metab Dispos. 2014 Oct;42(10):1698-707. doi: 10.1124/dmd.114.059626. Epub 2014 Jul 29.

31.

Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4.

Sager JE, Lutz JD, Foti RS, Davis C, Kunze KL, Isoherranen N.

Clin Pharmacol Ther. 2014 Jun;95(6):653-62. doi: 10.1038/clpt.2014.50. Epub 2014 Feb 25.

32.

Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study.

Ghrénassia E, Avouac J, Khanna D, Derk CT, Distler O, Suliman YA, Airo P, Carreira PE, Foti R, Granel B, Berezne A, Cabane J, Ingegnoli F, Rosato E, Caramaschi P, Hesselstrand R, Walker UA, Alegre-Sancho JJ, Zarrouk V, Agard C, Riccieri V, Schiopu E, Gladue H, Steen VD, Allanore Y.

J Rheumatol. 2014 Jan;41(1):99-105. doi: 10.3899/jrheum.130386. Epub 2013 Dec 1.

PMID:
24293584
33.

High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register.

Iannone F, Gremese E, Gallo G, Sarzi-Puttini P, Botsios C, Trotta F, Gasperini S, Galeazzi M, Adami S, Cantini F, Sebastiani M, Gorla R, Marchesoni A, Giardina A, Foti R, Mele A, Bruschi E, Bagnato G, Erre GL, Lapadula G; GISEA (Gruppo Italiano Studio Early Arthritis).

Clin Rheumatol. 2014 Jan;33(1):31-7. doi: 10.1007/s10067-013-2348-6. Epub 2013 Aug 18.

PMID:
23954923
34.

Regional differences of vitamin D deficiency in rheumatoid arthritis patients in Italy.

Rossini M, D'Avola G, Muratore M, Malavolta N, Silveri F, Bianchi G, Frediani B, Minisola G, Sorgi ML, Varenna M, Foti R, Tartarelli G, Orsolini G, Adami S; Study Group on Osteoporosis and Metabolic Skeletal Diseases of the Italian Society of Rheumatology (SIR).

Reumatismo. 2013 Jul 23;65(3):113-20. doi: 10.4081/reumatismo.2013.113.

35.

Signs of critical transition in the Everglades wetlands in response to climate and anthropogenic changes.

Foti R, del Jesus M, Rinaldo A, Rodriguez-Iturbe I.

Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6296-300. doi: 10.1073/pnas.1302558110. Epub 2013 Apr 1.

36.

Evaluation of UGT protein interactions in human hepatocytes: effect of siRNA down regulation of UGT1A9 and UGT2B7 on propofol glucuronidation in human hepatocytes.

Konopnicki CM, Dickmann LJ, Tracy JM, Tukey RH, Wienkers LC, Foti RS.

Arch Biochem Biophys. 2013 Jul 15;535(2):143-9. doi: 10.1016/j.abb.2013.03.012. Epub 2013 Apr 4.

37.

Maximum entropy production, carbon assimilation, and the spatial organization of vegetation in river basins.

del Jesus M, Foti R, Rinaldo A, Rodriguez-Iturbe I.

Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):20837-41. doi: 10.1073/pnas.1218636109. Epub 2012 Dec 3.

38.

Hydroperiod regime controls the organization of plant species in wetlands.

Foti R, del Jesus M, Rinaldo A, Rodriguez-Iturbe I.

Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19596-600. doi: 10.1073/pnas.1218056109. Epub 2012 Nov 13.

39.

Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors.

Foti RS, Pearson JT, Wong SL, Zalikowski JA, Boudreaux MD, Prokop SP, Davis JA, Banfield C, Emery MG, Rock DA, Wahlstrom JL, Wienkers LC, Amore BM.

Drug Metab Dispos. 2012 Dec;40(12):2239-49. doi: 10.1124/dmd.112.047928. Epub 2012 Aug 28.

40.

Cytochrome p450 architecture and cysteine nucleophile placement impact raloxifene-mediated mechanism-based inactivation.

VandenBrink BM, Davis JA, Pearson JT, Foti RS, Wienkers LC, Rock DA.

Mol Pharmacol. 2012 Nov;82(5):835-42. doi: 10.1124/mol.112.080739. Epub 2012 Aug 2.

41.

Mouse Rif1 is a key regulator of the replication-timing programme in mammalian cells.

Cornacchia D, Dileep V, Quivy JP, Foti R, Tili F, Santarella-Mellwig R, Antony C, Almouzni G, Gilbert DM, Buonomo SB.

EMBO J. 2012 Sep 12;31(18):3678-90. doi: 10.1038/emboj.2012.214. Epub 2012 Jul 31.

42.

Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine.

Gremese E, Carletto A, Padovan M, Atzeni F, Raffeiner B, Giardina AR, Favalli EG, Erre GL, Gorla R, Galeazzi M, Foti R, Cantini F, Salvarani C, Olivieri I, Lapadula G, Ferraccioli G; Gruppo Italiano di Studio sulle Early Arthritis (GISEA).

Arthritis Care Res (Hoboken). 2013 Jan;65(1):94-100. doi: 10.1002/acr.21768.

43.

Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.

Foti RS, Rock DA, Han X, Flowers RA, Wienkers LC, Wahlstrom JL.

J Med Chem. 2012 Feb 9;55(3):1205-14. doi: 10.1021/jm201346g. Epub 2012 Jan 31.

PMID:
22239545
44.

Brief report: successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter study.

Taraborelli M, Ramoni V, Brucato A, Airò P, Bajocchi G, Bellisai F, Biasi D, Blagojevic J, Canti V, Caporali R, Caramaschi P, Chiarolanza I, Codullo V, Cozzi F, Cuomo G, Cutolo M, De Santis M, De Vita S, Di Poi E, Doria A, Faggioli P, Favaro M, Ferraccioli G, Ferri C, Foti R, Gerosa A, Gerosa M, Giacuzzo S, Giani L, Giuggioli D, Imazio M, Iudici M, Iuliano A, Leonardi R, Limonta M, Lojacono A, Lubatti C, Matucci-Cerinic M, Mazzone A, Meroni M, Meroni PL, Mosca M, Motta M, Muscarà M, Nava S, Padovan M, Pagani G, Paolazzi G, Peccatori S, Ravagnani V, Riccieri V, Rosato E, Rovere-Querini P, Salsano F, Santaniello A, Scorza R, Tani C, Valentini G, Valesini G, Vanoli M, Vigone B, Zeni S, Tincani A; IMPRESS Investigators.

Arthritis Rheum. 2012 Jun;64(6):1970-7. doi: 10.1002/art.34350. Epub 2011 Dec 28.

45.

Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition.

VandenBrink BM, Foti RS, Rock DA, Wienkers LC, Wahlstrom JL.

Drug Metab Dispos. 2012 Jan;40(1):47-53. doi: 10.1124/dmd.111.041210. Epub 2011 Oct 5.

46.

The PML nuclear bodies-associated protein TTRAP regulates ribosome biogenesis in nucleolar cavities upon proteasome inhibition.

Vilotti S, Biagioli M, Foti R, Dal Ferro M, Lavina ZS, Collavin L, Del Sal G, Zucchelli S, Gustincich S.

Cell Death Differ. 2012 Mar;19(3):488-500. doi: 10.1038/cdd.2011.118. Epub 2011 Sep 16.

47.

Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate.

VandenBrink BM, Foti RS, Rock DA, Wienkers LC, Wahlstrom JL.

Drug Metab Dispos. 2011 Sep;39(9):1546-54. doi: 10.1124/dmd.111.039065. Epub 2011 Jun 22.

48.

Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.

Foti RS, Rock DA, Pearson JT, Wahlstrom JL, Wienkers LC.

Drug Metab Dispos. 2011 Jul;39(7):1188-95. doi: 10.1124/dmd.111.038505. Epub 2011 Mar 29.

49.

Catalytic versus inhibitory promiscuity in cytochrome P450s: implications for evolution of new function.

Foti RS, Honaker M, Nath A, Pearson JT, Buttrick B, Isoherranen N, Atkins WM.

Biochemistry. 2011 Apr 5;50(13):2387-93. doi: 10.1021/bi1020716. Epub 2011 Mar 11.

50.

Comparison of the Recent-Onset Arthritis Disability questionnaire with the Health Assessment Questionnaire disability index in patients with rheumatoid arthritis.

Salaffi F, Ciapetti A, Gasparini S, Migliore A, Scarpellini M, Corsaro SM, Laganà B, Mozzani F, Varcasia G, Pusceddu M, Castriotta M, Serale F, Maier A, Foti R, Scarpa R, Bombardieri S; NEW INDICES Study Group.

Clin Exp Rheumatol. 2010 Nov-Dec;28(6):855-65. Epub 2011 Jan 3.

PMID:
21122262

Supplemental Content

Support Center